Securing the IL-6 Receptor Market with the First EU Approval

Fresenius Kabi Deutschland's Tyenne (tocilizumab) is a biosimilar to Roche's Actemra/RoActemra (tocilizumab), which blocks the interleukin-6 receptor (IL-6R). The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on July 20, 2023, and the European Commission granted marketing authorization valid throughout the EU on September 15. As a result, Tyenne became the first tocilizumab biosimilar to be approved and launched in Europe in November 2023. A key commercial advantage is that it offers both intravenous (IV) and 162mg subcutaneous (SC) formulations, allowing it to target both hospital administration and self-administration needs.

Equivalence Supported by a Phase 3 Clinical Trial Involving 604 Patients

The approval is based on the APTURA I study (NCT04512001), a randomized, double-blind, Phase 3 clinical trial involving 604 patients with moderate-to-severe rheumatoid arthritis. The trial compared Tyenne's development code MSB11456 with EU-approved RoActemra up to 24 weeks, followed by continued administration or switching to Tyenne up to 52 weeks. The EMA concluded that the product is highly similar in terms of structure, purity, biological activity, and pharmacokinetics, and that there are no clinically meaningful differences in efficacy, safety, or immunogenicity. Based on the comprehensive data obtained in rheumatoid arthritis, the indications for giant cell arteritis, juvenile idiopathic arthritis, CAR-T-induced cytokine release syndrome (CRS), and severe COVID-19 were extrapolated from the originator.

Targeting the CHF 2.6 Billion Blockbuster with Price Pressure

Roche's Actemra/RoActemra recorded global sales of CHF 2.63 billion in 2023, demonstrating a proven revenue base that Tyenne can penetrate. The standard treatment for rheumatoid arthritis includes disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, TNF inhibitors such as adalimumab, and JAK inhibitors such as tofacitinib, leading to intense competition among treatment groups. Tyenne can directly target European hospital tenders and demand for cost savings by supplying the same molecule at a lower procurement price. However, the actual rate of revenue conversion depends on country-specific reimbursement, tendering cycles, supply stability, and the discount compared to the originator.

Narrowing the Monopoly Window with Subsequent Biosimilar Approvals

The period of market exclusivity is limited. Biogen's Tofidence received EU approval on June 20, 2024, as STADA Arzneimittel's tocilizumab STADA, and Celltrion's Avtozma received approval on February 14, 2025. Both products are IL-6R-targeting tocilizumab biosimilars with IV and SC administration routes, and compete directly with Tyenne. Tyenne has also expanded its regulatory validation by receiving FDA approval for both IV and SC formulations in the United States on March 5, 2024, but in the EU, it has already entered a multi-party price competition phase. Therefore, early contract wins, prescription retention rates, production costs, and supply reliability are key to long-term value, rather than the initial approval itself.